

## Polygenetik der koronaren Herzkrankheit

M. E. Kleber

### Literatur:

1. Dawber TR et al., An approach to longitudinal studies in a community: the Framingham Study. *Ann N Y Acad Sci*, 1963; 107: 539–56
2. Myers RH et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. *Am Heart J*, 1990; 120(4): 963–9
3. Schildkraut JM et al. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. *Am J Cardiol*, 1989; 64(10): 555–9
4. Boer JM et al. The joint impact of family history of myocardial infarction and other risk factors on 12-year coronary heart disease mortality. *Epidemiology*, 1999; 10(6): 767–70
5. Marenberg ME et al., Genetic susceptibility to death from coronary heart disease in a study of twins. *N Engl J Med*, 1994; 330(15): 1041–6
6. Zdravkovic S et al., Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. *J Intern Med* 2002; 252(3): 247–54
7. Won HH et al. Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease. *PLoS Genet*, 2015; 11(10): e1005622
8. Goldstein JL & Brown MS. The LDL receptor. *Arterioscler Thromb Vasc Biol* 2009; 29(4): 431–8
9. Ozaki K et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. *Nat Genet* 2002; 32(4): 650–4
10. Helgadottir A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* 2007; 316(5830): 1491–3
11. McPherson R et al. A common allele on chromosome 9 associated with coronary heart disease. *Science* 2007; 316(5830): 1488–91
12. Samani NJ et al. Genomewide association analysis of coronary artery disease. *N Engl J Med* 2007; 357(5): 443–53
13. Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 2011; 43(4): 333–8
14. Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet* 2013; 45(1): 25–33
15. Nikpay M et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 2015; 47(10): 1121–30
16. Aragam KG et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet* 2022; 54(12): 1803–15
17. Lo Sardo V et al. Unveiling the Role of the Most Impactful Cardiovascular Risk Locus through Haplotype Editing. *Cell* 2018; 175(7): 1796–1810.e20
18. Klarin D et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. *Nat Genet* 2017; 49(9): 1392–97

19. Tikkanen E et al. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. *Arterioscler Thromb Vasc Biol* 2013; 33(9): 2261–6
  20. Khera AV et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. *N Engl J Med* 2016; 375(24): 2349–58
  21. Inouye M et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. *J Am Coll Cardiol* 2018; 72(16): 1883–93
  22. Khera AV et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet* 2018; 50(9): 1219–24
  23. Mosley JD et al. Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. *JAMA* 2020; 323(7): 627–35
  24. Mega JL et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. *Lancet* 2015; 385(9984): 2264–71
- 

## Genetik der Kardiomyopathien

*D. Oehler*

### Literatur:

1. Arbelo E et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). *Eur Heart J* 2023; 44(37): 3503–626
2. Wijnker PJM et al. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors. *Cardiovascular Research* 2024
3. Maron BA et al. What Causes Hypertrophic Cardiomyopathy? *Am J Cardiol* 2022; 179: 74–82
4. Kayvanpour E et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. *Clin Res Cardiol* 2017; 106(2): 127–39
5. Haas J et al. Atlas of the clinical genetics of human dilated cardiomyopathy. *Eur Heart J* 2014; 36(18): 1123–35
6. Oehler D et al. Genetik bakom dilaterad kardiomyopati och kliniska konsekvenser. *BestPractice Nordic* 2020(NR 1 / 2020)
7. Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. *Genome Medicine* 2017; 9(1): 20
8. Wolf CM et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. *J Molec Cell Cardiol* 2008; 44(2): 293–303
9. Goidescu CM. Dilated cardiomyopathy produced by lamin A/C gene mutations. *Clujul Med* 2013; 86(4): 309–12
10. Oehler D, Katus HA, Meder B. Genetics of Cardiomyopathies - Dilated cardiomyopathy. In: *The ESC textbook of cardiovascular medicine*. Third edition ed. Oxford: Oxford University Press/European Society of Cardiology Oxford; 2019

11. Lehman SJ, Crocini C, Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies. *Nature Rev Cardiol* 2022; 19(6): 353–63
  12. Marian AJ. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. *Circ Res* 2021; 128(10): 1533–53
  13. O'Mahony C et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J* 2014; 35(30): 2010–20
  14. Krahn AD et al. Arrhythmogenic Right Ventricular Cardiomyopathy. *JACC: Clinical Electrophysiology* 2022; 8(4): 533–53
  15. Corrado D et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. *Int J Cardiol* 2020; 319: 106–14
  16. Olivotto I et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2020; 396(10253): 759–69
  17. Oehler D, Moog U. Praktischer Ablauf. In: *Genetische Kardiomyopathien. Leitfaden für den klinischen Alltag*. Benjamin M, editor. Berlin, Boston: De Gruyter; 2017
- 

## **Familiäre Hypercholesterinämie – noch immer unterdiagnostiziert und unterbehandelt**

*F. Fath, W. März*

### **Literatur:**

1. Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 2017; 38: 2459–72
2. Ference BA et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol* 2012; 60: 2631–39
3. Zhang Y et al. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. *JAMA Cardiology* 2021; 6: 1406–13
4. Organization WH. *Cardiovascular diseases (CVDs) 2021*
5. Bundesamt S. Gesundheit. *Todesursachen 2022*
6. Martin SS et al. Lipid distributions in the Global Diagnostics Network across five continents. *Eur Heart J* 2023; 44: 2305–18
7. Sturm AC et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *J Am Coll Cardiol* 2018; 72: 662–80
8. Beheshti SO et al. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. *J Am Coll Cardiol* 2020; 75: 2553–66
9. Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013; 34: 3478–3490a

10. Meshkov AN et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. *J Pers Med* 2021
11. Descamps OS et al. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. *Atherosclerosis* 2021; 157: 514–18
12. Schmidt N et al. Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study. *Atherosclerosis* 2017; 266, 24–30
13. Mundal L et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. *J Am Heart Assoc* 2014; 3: e001236
14. Versmissen J et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ* 2008; 337: a2423
15. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020; 41: 111–88
16. Cuchel M et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J* 2023; 44: 2277–91
17. Tromp TR et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. *Lancet* 2022; 399: 719–28
18. Klose G et al. Familial hypercholesterolemia: developments in diagnosis and treatment. *Dtsch Arztebl Int* 2014; 111: 523–29
19. Widhalm K et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. *J Pediatr* 2011; 158: 167
20. Collaboration EA et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis* 2018; 277: 234–55
21. Cuchel M et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. *Lancet* 2013; 381: 40–46
22. Boey E et al. Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. *Atherosclerosis* 2016; 244: 86–92
23. Thompson GR et al. Efficacy criteria and cholesterol targets for LDL apheresis. *Atherosclerosis* 2010; 208: 317–21
24. Maucher IV. Evolocumab. 2021
25. Maucher IV. Evinacumab. 2023
26. Gidding SS & Hegele RA. Introducing Personalized Medicine Into Pediatric Homozygous Familial Hypercholesterolemia Care. *Arterioscler Thromb Vasc Biol* 2022; 42: 1458–60
27. Defesche JC et al. Advanced method for the identification of patients with inherited hypercholesterolemia. *Semin Vasc Med* 2004; 4: 59–65
28. Marks D et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis* 2023; 168: 1–14
29. Grenkowitz T et al. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. *Atherosclerosis* 2016; 253: 88–93

30. Khera AV et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J Am Coll Cardiol* 2016; 67: 2578–89
  31. März W et al. The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment. *Atherosclerosis Plus* 2023; 53: 6–15
  32. Lee S et al. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. *Eur J Prev Cardiol* 2019; 26: 1262–70
  33. Umans-Eckenhausen MA et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. *Arch Intern Med*. 2003; 163: 65–8
  34. Shalev V et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. *Arch Intern Med* 2009; 169: 260–68
  35. Zafrir B & Jubran A. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic. *Cardiovasc Ther* 2018; 36: e12439
  36. Barkas F et al. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. *Nutrients* 2020; 12
  37. Taylor A et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. *Clin Genet* 2010; 77: 572–80
  38. Leren TP et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. *Community Genet* 2008; 11: 26–35
  39. Sharma P et al. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. *Health Technol Assess* 2012; 16: 1–266
  40. Krawczak M et al. Estimating the efficacy and efficiency of cascade genetic screening. *Am J Hum Genet* 2001; 69: 361–70
  41. Umans-Eckenhausen MA et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. *Lancet* 2001; 357: 165–68
  42. Rosso A et al. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review. *Ann Ig* 2017; 29: 464–80
  43. Louter L et al. Cascade screening for familial hypercholesterolemia: Practical consequences. *Atheroscler Suppl* 2017; 30: 77–85
  44. Leren TP & Bogsrud MP. Cascade screening for familial hypercholesterolemia should be organized at a national level. *Curr Opin Lipidol* 2022; 33: 231–36
  45. Leren TP et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. *Semin Vasc Med* 2004; 4: 75–85
  46. Page C et al. A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK's NHS long term plan. *PLOS Glob Public Health* 2023; 3: e0001795
  47. Schmidt N et al. CaRe high - Cascade screening and registry for high cholesterol in Germany. *Atheroscler Suppl* 2017; 30: 72–76
-

# Genetik bei Nierenerkrankungen

*U. T. Schultheiss, E. Wohlleber, J. Kohlhasse*

## Literatur:

1. Thompson WS et al. State of the Science and Ethical Considerations for Preimplantation Genetic Testing for Monogenic Cystic Kidney Diseases and Ciliopathies. *J Am Soc Nephrol* 2023
2. Senum SR et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. *Am J Hum Genet* 2022; 109(1): 136–56
3. Cornec-Le Gall E et al. Autosomal dominant polycystic kidney disease. *Lancet* 2019; 393(10174): 919–35
4. Savige J & Harraka P. Pathogenic Variants in the Genes Affected in Alport Syndrome (COL4A3-COL4A5) and Their Association With Other Kidney Conditions: A Review. *Am J Kidney Dis* 2021; 78(6): 857–64
5. Savige J et al. Guidelines for Genetic Testing and Management of Alport Syndrome. *Clin J Am Soc Nephrol* 2022; 17(1): 143–54
6. Devuyt O et al. Autosomal dominant tubulointerstitial kidney disease. *Nat Rev Dis Primers* 2019; 5(1): 60
7. Ayasreh N et al. Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1. *Am J Kidney Dis* 2018; 72(3): 411–18
8. Sharp A et al. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. *Hum Genet* 2000; 107(4): 343–9
9. Kirby A et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nat Genet* 2013; 45(3): 299–303
10. Hart TC et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. *J Med Genet* 2002; 39(12): 882–92
11. Zivná M et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. *Am J Hum Genet* 2009; 85(2): 204–13
12. Lindner TH et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. *Hum Mol Genet* 1999; 8(11): 2001–8
13. Snoek R et al. Preimplantation Genetic Testing for Monogenic Kidney Disease. *Clin J Am Soc Nephrol* 2020; 15(9): 1279–86
14. De Rycke M & Berckmoes V. Preimplantation Genetic Testing for Monogenic Disorders. *Genes (Basel)* 2020; 11(8)
15. Peces R et al. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan. *Clin Kidney J* 2021; 14(8): 1987–89
16. Harton GL et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD. *Hum Reprod* 2011; 26(1): 33–40

17. Rechitsky S et al. PGD for cystic fibrosis patients and couples at risk of an additional genetic disorder combined with 24-chromosome aneuploidy testing. *Reprod Biomed Online* 2013; 26(5): 420–30
  18. Kuliev A et al. PGD for inherited cardiac diseases. *Reprod Biomed Online* 2012; 24(4): 443–53
  19. Berckmoes V et al. Factors influencing the clinical outcome of preimplantation genetic testing for polycystic kidney disease. *Hum Reprod* 2019; 34(5): 949–58
  20. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020; 395: 709–33
  21. Zhang J et al. Familial Aggregation of CKD and Heritability of Kidney Biomarkers in the General Population: The Lifelines Cohort Study. *Am J Kidney Dis* 2021; 77(6): 869–78
  22. Wuttke M et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet* 2019; 51(6): 957–72
  23. Cocchi E et al. Clinical Genetic Screening in Adult Patients with Kidney Disease. *Clin J Am Soc Nephrol* 2020; 15(10): 1497–510
- 

## Individualisierte Therapie des Typ-2-Diabetes

*B. Gallwitz*

### Literatur:

1. Tönnies T et al. Diabetes free life expectancy and years of life lost associated with type 2 diabetes: projected trends in Germany between 2015 and 2040. *Popul Health Metr* 2021; 19: 38
2. Ahlqvist E et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 2018; 6: 361–69
3. Davies MJ et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2022; 65: 1925–66
4. Draznin B et al. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2022. *Diabetes Care* 2022; 45(1): 125–43
5. BÄK et al. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Teilpublikation der Langfassung. 2021
6. Landgraf R et al. Therapie des Typ-2-Diabetes. *Diabetologie* 2022; 17(2): 159–204
7. Sanchez-Rangel E & Inzucchi SE. Metformin: clinical use in type 2 diabetes. *Diabetologia* 2017; 60: 1586–93
8. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352: 854–65
9. McGill JB. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. *Curr Diabetes Rev* 2012; 8: 257–67

10. Bannister CA et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. *Diabetes Obes Metab* 2014; 16: 1165–73
11. Breuer TGK & Meier JJ. Inpatient treatment of type 2 diabetes. *Dtsch Arztebl Int* 2012; 109: 466–74
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. *Mol Metab* 2021; 46: 101102
13. Gallwitz B. Clinical Use of DPP-4 Inhibitors. *Front Endocrinol (Lausanne)*. 2019; 10: 389
14. Rosenstock J et al. CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *JAMA* 2019; 322: 1155–66
15. Bennett WL et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. *Ann Intern Med* 2011; 154: 602–13
16. Lee MMY et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. *Diabetes Metab Syndr* 2022; 16: 102382
17. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. *Drug Des Devel Ther* 2014; 8: 1335–80
18. Zinman B et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015; 373: 2117–28
19. Wiviott SD et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2019; 380: 347–57
20. Cannon CP et al. VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. *N Engl J Med* 2020; 383: 1425–35
21. Palmer SC et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ* 2021; 372: m4573
22. Cosentino F et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020; 41: 255–323
23. Diamant M et al. 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. *Diabetes Care* 2014; 37: 2763–73
24. Ahmann A et al. NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2015; 17: 1056–64